RNS Number : 5003E
e-Therapeutics plc
08 May 2017




e-Therapeutics plc

('e-Therapeutics' or the 'Company')


Notice of Annual General Meeting and Annual Report



Oxford, UK, 8 May 2017 - e-Therapeutics plc (AIM: ETX) announces that its annual report and accounts for the year ended 31 January 2017, which includes the notice convening the Company's 2017 Annual General Meeting (AGM), has been posted to shareholders today.


An electronic copy of the annual report can be downloaded from the Company's website at  

The 2017 AGM will take place at 11:00 am on 31 May 2017 at the offices of Stephenson Harwood LLP, 1 Finsbury Circus, London EC2M 7SH.





e-Therapeutics plc

Ray Barlow, CEO

Steve Medlicott, Finance Director


Tel: +44 (0) 1993 883 125 


Numis Securities Limited

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Corporate Broking)


Tel: +44 (0) 207 260 1000


Instinctif Partners

Melanie Toyne Sewell / Alex Shaw

Tel: +44 (0) 207 457 2020




About e-Therapeutics plc

e-Therapeutics is a drug discovery company with a unique and proprietary in silico discovery platform.  The Company is applying its computational platform to the discovery of new drug candidates for which it can secure robust intellectual property rights.

The therapeutic focus of the Company's discovery activity is in areas of complex disease with unmet medical need, including immuno-oncology.  The business model is to partner these preclinical drug candidates.

e-Therapeutics is headquartered in Oxford. For more information about the Company please visit




This information is provided by RNS
The company news service from the London Stock Exchange